信号转换器和转录激活器4 (STAT4) 与垂体腺瘤相关联
Greta Gedvilaite-Vaicechauskiene1, Loresa Kriauciuniene1, Rasa Liutkeviciene1
1Laboratory of Ophthalmology, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu 2, LT-50161 Kaunas, Lithuania.
信号转换器和转录激活器4 (STAT4) 基因变异和血清水平升高与垂体腺瘤 (PA) 的发生,大小和复发有关. 这些发现表明STAT4
科学领域:
- 免疫遗传学 免疫遗传学
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
背景情况:
- 垂体腺瘤 (PAs) 是一种常见的瘤,具有复杂的发病因子.
- 免疫反应调节在PA发展和进展中的作用越来越被认可.
研究的目的:
- 研究信号转换器和转录4 (STAT4) 激活器多形态和血清水平与垂体腺瘤的发生,大小和复发之间的关联.
- 探索STAT4在抗瘤免疫和PA病原发生中的潜在作用.
主要方法:
- 使用实时PCR对四种STAT4单核酸多态 (SNP) (rs7574865,rs10181656,rs7574865和rs10168266) 的基因型定型.
- 通过ELISA量化血清STAT4水平.
- 统计分析包括二进制物流回归和按性别分层.
主要成果:
- 特定的STAT4基因型 (rs7574865 GT+GG,rs10168266 CC+CT) 与PA发生的几率增加有关,特别是在男性中.
- 在宏观PA中,STAT4 rs7574865 GG基因型的发生频率较低,G基因元/GT+GG基因型与复发风险降低有关.
- 在PA患者中,血清STAT4水平显著更高,特定的基因型与高水平相关.
结论:
- STAT4基因型与垂体腺瘤的发生,大小和复发显著相关.
- 在PA患者中血清STAT4水平升高表明其参与PA的发病.
- STAT4可能是潜在的治疗标或垂体腺瘤的生物标志物.
更多相关视频
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
相关概念视频
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Amplifying Signals via Enzymatic Cascade
